MAD1L1 and cancer: The fusion protein RARS-mitotic arrest deficient 1-like 1 (MAD1L1) activated the FBP/c-Myc pathway by interacting with AIMP2, thereby inducing cancer stem cell-like phenotypes (Zhong et al., 2018).